Signals, Powered By EquityPandit
Strides Shasun has received an Establishment Inspection Report (EIR) from the US health regulator for its formulations facility at Bengaluru.
Strides said in a BSE filing that “The company’s formulations facility (KRSG Gardens) in Bengaluru which was inspected by the USFDA in May 2017 has received the EIR, thereby confirming the closure of the inspection.”
The KRSG Gardens facility conducts manufacturing of tablets, capsules, liquids, sachets, creams and ointments.
The facility does support the important current and future products for the US market.
